|Over a week ago|
Largest borrow rate increases among liquid names » 08:4506/2406/24/20
NKLA, ACB, CLIR, SRNE, ATNM, TXMD, NEPT, BBBY, CEMI, BCLI
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: (NKLA) 962.76% +4.10, Aurora Cannabis (ACB) 68.78% +2.13, ClearSign Combustion (CLIR) 97.37% +1.79, Sorrento Therapeutics (SRNE) 135.42% +0.91, Actinium Pharmaceuticals (ATNM) 3.47% +0.68, TherapeuticsMD (TXMD) 21.21% +0.64, Neptune Technologies (NEPT) 50.80% +0.53, Bed Bath & Beyond (BBBY) 6.42% +0.47, Chembio Diagnostics (CEMI) 3.39% +0.40, and BrainStorm (BCLI) 11.12% +0.40.
Largest borrow rate increases among liquid names » 08:4506/0806/08/20
ADAP, MGI, TXMD, ASHR, NAT, SAVE, TLRD, FRO, BLDP, WRTC
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: Adaptimmune (ADAP) 79.23% +19.41, MoneyGram (MGI) 7.88% +6.32, TherapeuticsMD (TXMD) 11.29% +1.25, db X trackers China (ASHR) 16.57% +0.75, Nordic American Tankers (NAT) 17.37% +0.70, Spirit Airlines (SAVE) 10.77% +0.51, Tailored Brands (TLRD) 95.13% +0.44, Frontline (FRO) 23.43% +0.41, Ballard Power (BLDP) 24.88% +0.30, and Wrap Technologies (WRTC) 49.62% +0.21.
|Over a month ago|
TherapeuticsMD CFO Daniel Cartwright retires, James D'Arecca to succeed » 06:5206/0106/01/20
TherapeuticsMD announced the appointment of James D'Arecca as the company's CFO, effective June 1. D'Arecca succeeds Daniel Cartwright, who has retired from his position as the company's CFO, also effective June 1. Cartwright will remain with the company as an advisor for a transitional period. D'Arecca joins TherapeuticsMD with broad experience in corporate and operational finance, most recently as Senior Vice President and Chief Accounting Officer of Allergan.
Largest borrow rate increases among liquid names » 08:4505/2705/27/20
LSCC, APRN, EWH, KL, NEPT, TXMD, VHC, AG, GOGO, ERI
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: Lattice Semiconductor (LSCC) 0.97% +0.63, Blue Apron (APRN) 61.36% +0.22, iShares Hong Kong (EWH) 1.16% +0.20, Kirkland Lake Gold (KL) 0.48% +0.18, Neptune Technologies (NEPT) 48.15% +0.17, TherapeuticsMD (TXMD) 10.46% +0.15, VirnetX (VHC) 1.14% +0.13, First Majestic Silver (AG) 0.81% +0.12, Gogo (GOGO) 40.36% +0.11, and Eldorado Resorts (ERI) 3.75% +0.09.
Fly Intel: Top five analyst downgrades » 10:1105/1905/19/20
DIS, CMCSA, EXPE, NOVA, TXMD
Catch up on today's…
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Loop Capital with analyst Alan Gould saying the Street is overestimating the speed of recovery from the pandemic, while the loss of the company's Streaming business head Kevin Mayer announced yesterday adds to the uncertainty. 2. Comcast (CMCSA) downgraded to Neutral from Buy at Guggenheim with analyst Mike McCormack saying he sees NBCUniversal being "particularly challenged" given its exposure to theme parks, filmed entertainment, and advertising. 3. Expedia (EXPE) downgraded to Hold from Buy at Jefferies with analyst Brent Thill saying although Expedia and Booking Holdings (BKNG) are trading just above trough multiples, he's cautious on the stocks "as the recovery could be more prolonged than past downturns." 4. Sunnova Energy (NOVA) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Weinstein saying the company remains a "great story" and the desire of its management to shore up capital during uncertain times is "understandable" given its working capital needs during its growth phase. 5. TherapeuticsMD (TXMD) downgraded to Neutral from Overweight at JPMorgan with analyst Christopher Schott saying disruptions caused by COVID-19 have placed the company in a "difficult position," having to balance its commercial investments against cash burn considerations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TherapeuticsMD downgraded to Neutral on COVID disruptions at JPMorgan » 06:1005/1905/19/20
JPMorgan analyst Christopher Schott downgraded TherapeuticsMD to Neutral from Overweight without a price target. Disruptions caused by COVID-19 have placed the company in a "difficult position," having to balance its commercial investments against cash burn considerations, Schott tells investors in a research note. The analyst also sees less certainty on the commercial outlook for TherapeuticsMD's products post-COVID.
TherapeuticsMD downgraded to Neutral from Overweight at JPMorgan » 05:3205/1905/19/20
JPMorgan analyst Christopher Schott downgraded TherapeuticsMD to Neutral from Overweight.
Largest borrow rate increases among liquid names » 08:4505/0805/08/20
I, WLL, AAL, MVIS, HTZ, TXMD, AMC, JNUG, NCLH, UUUU
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: Intelsat (I) 60.10% +10.28, Whiting Petroleum (WLL) 161.29% +7.71, American Airlines (AAL) 29.31% +3.86, Microvision (MVIS) 39.69% +2.41, Hertz (HTZ) 80.10% +0.48, TherapeuticsMD (TXMD) 12.77% +0.30, AMC Entertainment (AMC) 101.78% +0.28, Direxion Junior Gold (JNUG) 3.12% +0.20, Norwegian Cruise Line (NCLH) 1.58% +0.07, and Energy Fuels (UUUU) 6.20% +0.07.
TherapeuticsMD price target lowered to $5 from $6 at H.C. Wainwright » 07:1605/0705/07/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Douglas Tsao lowered the firm's price target on TherapeuticsMD to $5 from $6 and reiterates a Buy rating on the shares. Management indicated they hoped to achieve EBITDA breakeven by 2021, which the analyst says isn't unrealistic, but he models the company achieving that milestone in 2022 given the uncertainties created by COVID-19. The new price target price is based on more conservative expectations for TherapeuticsMD's revenue trajectory.
TherapeuticsMD reports Q1 EPS (21c), consensus (19c) » 07:1005/0605/06/20
Reports Q1 revenue…
Reports Q1 revenue $12.3M, consensus $11.3M. The company has initiated measures to reduce its operating expenses for Q2 by $10M-$12M and plans to further reduce total operating expenses to approximately $40M or below for Q3 and Q4. The company's goal still remains to achieve EBITDA break even in 2021. CEO Robert Finizio stated, "We delivered a solid quarter in revenue. Recently, we extended the value of our lead asset, ANNOVERA, with the first Orange Book listed patent, and revised our strategic priorities and significantly reduced our operating cost structure, bringing us closer to achieving EBITDA break even in 2021."